Emerging research suggest Retatrutide , a dual agonist targeting both incretin and another hormone, may offer a significant advancement for body loss . Early clinical trials have indicated considerable losses in visceral tissue, possibly surpassing current body composition treatments. However , further assessment is needed to completely understand